Home › Companies › Dyne Therapeutics, Inc. › 2025-2026

Dyne Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Dyne Therapeutics, Inc.’s Form 8-K, filed 2026-06-08 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
249Asset managers
1,962Fund votes
2026-06-05Meeting date

Proxy season: 2024-2025 2025-2026

Explore Dyne Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Dyne Therapeutics, Inc.

These tallies are Dyne Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Dyne Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: David Lubner	136,331,376	--	--	12,741,582	9,669,965	Majority: yes
Elect Director: Brian Posner	148,535,323	--	--	537,635	9,669,965	Majority: yes
Elect Director: Jason Rhodes	130,313,227	--	--	18,759,731	9,669,965	Majority: yes
b) The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.	147,732,142	1,279,302	61,514	--	9,669,965	Majority: yes
c) The stockholders of the Company approved an amendment to the Company's restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (the "Authorized Share	157,762,168	913,118	67,637	--	--	Majority: yes
The Company filed a certificate of amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware on June 8, 2026, to effect the Authorized Shares Amendment. d) The stockholders of the Company ap	136,735,765	12,310,752	26,441	--	9,669,965	Majority: yes
The Company filed a certificate of amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware on June 8, 2026, to effect the Officer Exculpation Amendment. e) The stockholders of the Company	158,690,016	25,660	27,247	--	--	Majority: yes

Source: Dyne Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-08 — read the filing on EDGAR.

How asset managers voted at the Dyne Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 249 asset managers that disclosed a Dyne Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Dyne Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 147,732,142AGAINST: 1,279,302

Dyne Therapeutics, Inc.’s own tally for this item (“b) The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”): 147,732,142 for, 1,279,302 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,201,329 outstanding shares: 89% for, 0.8% against (90% of the company cast a for/against vote).

The 248 asset managers below cast 99.6% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 99.5%

FOR: 99.5%AGAINST: 0.4%ABSTAIN: 0.1%NOT VOTED: 0.0%

Largest asset managers voting on “TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	54,405,462	0	For
Fidelity	17,953,141	0	For
Janus Henderson	14,674,324	0	For
Vanguard	11,880,165	1	For
BlackRock	9,774,684	11,920	For
Atlas Venture Life Science Advisors, LLC	9,130,465	0	For
Orbis Allan Gray Ltd	6,055,647	0	For
State Street	5,970,748	23,840	For
FCPM III SERVICES B.V.	4,644,386	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,460,784	0	For
Frazier Life Sciences Management, L.P.	3,153,082	0	For
ORBIMED ADVISORS LLC	2,917,884	0	For
JANUS INVESTMENT FUND	2,644,193	0	For
Polar Capital Holdings Plc	2,570,848	0	For
Vestal Point Capital, LP	2,416,199	0	For
Charles Schwab	2,317,927	0	For
Venrock Adviser, LLC	2,173,913	0	For
Siren, L.L.C.	2,021,069	0	For
FRANKLIN ADVISERS INC	1,977,885	0	For
Deep Track Capital, LP	1,948,539	0	For
Palo Alto Investors LP	1,647,521	0	For
Vivo Capital, LLC	1,557,466	0	For
Aberdeen	1,430,384	0	For
MPM BioImpact LLC	1,347,530	0	For
SAMLYN CAPITAL, LLC	1,343,752	0	For

Showing the 25 largest of 248 asset managers. See all 248 in the interactive database.

2. To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Brian Posner

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 148,535,323WITHHELD: 537,635

Dyne Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian Posner”): 148,535,323 for, 537,635 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,201,329 outstanding shares: 90% for, 0.4% withheld (90% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (61,591,877 for, 0 against).

FOR 99.9%

FOR: 61,591,877 (100.0%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	21,281,786	0	For
Vanguard	10,770,948	1	For
Fidelity	8,957,415	0	For
BlackRock	5,408,316	0	For
State Street	3,595,048	0	For
JANUS INVESTMENT FUND	2,644,193	0	For
JPMorgan	1,339,088	0	For
Charles Schwab	1,158,841	0	For
FRANKLIN STRATEGIC SERIES	987,061	0	For
Jackson National	766,487	0	For
TIAA	697,583	0	For
WASATCH FUNDS TRUST	433,765	0	For
Legg Mason	330,216	0	For
Voya	310,152	0	For
Equitable	283,639	0	For
PENN SERIES FUNDS INC	237,516	0	For
Northwestern Mutual	219,314	0	For
QUANTITATIVE MASTER SERIES LLC	206,225	0	For
John Hancock	167,452	0	For
Columbia Threadneedle	144,039	0	For
Victory Capital	143,089	0	For
Lincoln Financial	135,699	0	For
Brighthouse	120,702	0	For
Goldman Sachs	118,870	0	For
ProShares	108,297	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

3. To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: David Lubner

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 136,331,376WITHHELD: 12,741,582

Dyne Therapeutics, Inc.’s own tally for this item (“Elect Director: David Lubner”): 136,331,376 for, 12,741,582 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,201,329 outstanding shares: 83% for, 8% withheld (90% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (58,990,506 for, 0 against).

FOR 96%

FOR: 58,990,506 (95.8%)ABSTAIN: 2,601,372 (4.2%)

Largest asset managers voting on “To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	21,281,786	0	For
Vanguard	10,765,229	5,720	For
Fidelity	8,957,415	0	For
BlackRock	5,408,316	0	For
State Street	3,590,822	4,226	For
JANUS INVESTMENT FUND	2,527,189	117,004	For
JPMorgan	1,339,088	0	For
Charles Schwab	1,158,841	0	For
FRANKLIN STRATEGIC SERIES	0	987,061	Abstain
Jackson National	742,158	24,329	For
TIAA	0	697,583	Abstain
WASATCH FUNDS TRUST	433,765	0	For
Legg Mason	330,216	0	For
Voya	310,152	0	For
Equitable	192,439	91,200	For
PENN SERIES FUNDS INC	237,516	0	For
Northwestern Mutual	219,314	0	For
QUANTITATIVE MASTER SERIES LLC	206,225	0	For
John Hancock	132,331	35,121	For
Columbia Threadneedle	144,039	0	For
Victory Capital	0	143,089	Abstain
Lincoln Financial	83,800	51,899	For
Brighthouse	78,426	42,276	For
Goldman Sachs	118,870	0	For
ProShares	0	108,297	Abstain

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

4. To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Jason Rhodes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 130,313,227WITHHELD: 18,759,731

Dyne Therapeutics, Inc.’s own tally for this item (“Elect Director: Jason Rhodes”): 130,313,227 for, 18,759,731 withheld, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,201,329 outstanding shares: 79% for, 11% withheld (90% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (57,384,998 for, 0 against).

FOR 93%

FOR: 57,384,998 (93.2%)ABSTAIN: 4,206,880 (6.8%)

Largest asset managers voting on “To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	21,281,786	0	For
Vanguard	10,491,050	279,899	For
Fidelity	8,949,888	7,527	For
BlackRock	4,874,523	533,793	For
State Street	3,590,822	4,226	For
JANUS INVESTMENT FUND	2,527,189	117,004	For
JPMorgan	1,339,088	0	For
Charles Schwab	1,158,841	0	For
FRANKLIN STRATEGIC SERIES	0	987,061	Abstain
Jackson National	742,158	24,329	For
TIAA	0	697,583	Abstain
WASATCH FUNDS TRUST	433,765	0	For
Legg Mason	330,216	0	For
Voya	0	310,152	Abstain
Equitable	192,439	91,200	For
PENN SERIES FUNDS INC	237,516	0	For
Northwestern Mutual	219,314	0	For
QUANTITATIVE MASTER SERIES LLC	206,225	0	For
John Hancock	132,331	35,121	For
Columbia Threadneedle	0	144,039	Abstain
Victory Capital	0	143,089	Abstain
Lincoln Financial	83,800	51,899	For
Brighthouse	78,426	42,276	For
Goldman Sachs	118,870	0	For
ProShares	0	108,297	Abstain

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

5. TO APPROVE AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 200,000,000 SHARES TO 400,000,000 SHARES.

CAPITAL STRUCTUREMajority of the votes cast: yes

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 157,762,168AGAINST: 913,118

Dyne Therapeutics, Inc.’s own tally for this item (“c) The stockholders of the Company approved an amendment to the Company's restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (t”): 157,762,168 for, 913,118 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,201,329 outstanding shares: 95% for, 0.6% against (96% of the company cast a for/against vote).

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (61,586,609 for, 5,270 against).

FOR 99.9%

FOR: 61,586,609 (100.0%)AGAINST: 5,270 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHAR” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	21,281,786	0	For
Vanguard	10,770,948	1	For
Fidelity	8,957,415	0	For
BlackRock	5,408,316	0	For
State Street	3,595,012	36	For
JANUS INVESTMENT FUND	2,644,193	0	For
JPMorgan	1,339,088	0	For
Charles Schwab	1,158,841	0	For
FRANKLIN STRATEGIC SERIES	987,061	0	For
Jackson National	766,487	0	For
TIAA	697,583	0	For
WASATCH FUNDS TRUST	433,765	0	For
Legg Mason	330,216	0	For
Voya	310,152	0	For
Equitable	283,639	0	For
PENN SERIES FUNDS INC	237,516	0	For
Northwestern Mutual	219,314	0	For
QUANTITATIVE MASTER SERIES LLC	206,225	0	For
John Hancock	167,452	0	For
Columbia Threadneedle	144,039	0	For
Victory Capital	143,089	0	For
Lincoln Financial	135,699	0	For
Brighthouse	120,702	0	For
Goldman Sachs	118,870	0	For
ProShares	108,297	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

6. TO APPROVE AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO PROVIDE FOR OFFICER EXCULPATION.

SHAREHOLDER RIGHTS AND DEFENSESMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 158,690,016AGAINST: 25,660

Dyne Therapeutics, Inc.’s own tally for this item (“The Company filed a certificate of amendment to its restated certificate of incorporation with the Secretary of State of the State of Delaware on June 8, 2026, to effect the Officer Exculpation Amendment. e) The stockhol”): 158,690,016 for, 25,660 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 165,201,329 outstanding shares: 96% for, 0.1% against (96% of the company cast a for/against vote).

The 63 asset managers below cast 95% of the shares they voted on this item FOR (58,403,330 for, 3,188,548 against).

FOR 95%

FOR: 58,403,330 (94.8%)AGAINST: 3,188,548 (5.2%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO PROVIDE FOR OFFICER EXCULPATION.” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	21,281,786	0	For
Vanguard	10,491,058	279,891	For
Fidelity	8,957,415	0	For
BlackRock	5,408,316	0	For
State Street	3,593,876	1,172	For
JANUS INVESTMENT FUND	2,644,193	0	For
JPMorgan	0	1,339,088	Against
Charles Schwab	1,158,841	0	For
FRANKLIN STRATEGIC SERIES	0	987,061	Against
Jackson National	766,487	0	For
TIAA	697,583	0	For
WASATCH FUNDS TRUST	433,765	0	For
Legg Mason	0	330,216	Against
Voya	310,152	0	For
Equitable	283,639	0	For
PENN SERIES FUNDS INC	237,516	0	For
Northwestern Mutual	219,314	0	For
QUANTITATIVE MASTER SERIES LLC	206,225	0	For
John Hancock	167,452	0	For
Columbia Threadneedle	144,039	0	For
Victory Capital	143,089	0	For
Lincoln Financial	135,699	0	For
Brighthouse	120,702	0	For
Goldman Sachs	118,870	0	For
ProShares	108,297	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

7. TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 63 asset managers below cast 100% of the shares they voted on this item FOR (61,591,878 for, 0 against).

FOR: 61,591,878 (100.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at Dyne Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
T. Rowe Price	21,281,786	For
Vanguard	10,770,949	For
Fidelity	8,957,415	For
BlackRock	5,408,316	For
State Street	3,595,048	For
JANUS INVESTMENT FUND	2,644,193	For
JPMorgan	1,339,088	For
Charles Schwab	1,158,841	For
FRANKLIN STRATEGIC SERIES	987,061	For
Jackson National	766,487	For
TIAA	697,583	For
WASATCH FUNDS TRUST	433,765	For
Legg Mason	330,216	For
Voya	310,152	For
Equitable	283,639	For
PENN SERIES FUNDS INC	237,516	For
Northwestern Mutual	219,314	For
QUANTITATIVE MASTER SERIES LLC	206,225	For
John Hancock	167,452	For
Columbia Threadneedle	144,039	For
Victory Capital	143,089	For
Lincoln Financial	135,699	For
Brighthouse	120,702	For
Goldman Sachs	118,870	For
ProShares	108,297	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

Largest Dyne Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Dyne Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 165,201,329 shares outstanding at the time of that meeting.

Top Dyne Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	32.93%
2	Fidelity	10.87%
3	Janus Henderson	8.88%
4	Vanguard	7.19%
5	BlackRock	5.92%
6	Atlas Venture Life Science Advisors, LLC	5.53%
7	Orbis Allan Gray Ltd	3.67%
8	State Street	3.63%
9	FCPM III SERVICES B.V.	2.81%
10	GEODE CAPITAL MANAGEMENT, LLC	2.09%

Reported Dyne Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Dyne Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP PLC	8.26%	13G
JANUS HENDERSON GROUP Ltd.	7.26%	13G
BlackRock	7.08%	13F
Vanguard Group	6.79%	13F
FMR (Fidelity)	5.39%	13F
State Street	4.03%	13F
Atlas Venture Fund XI, L.P.	2.71%	13G
Geode Capital	2.12%	13F
JPMorgan Chase	1.97%	13F
T. Rowe Price	1.41%	13F

Percentages above are of 165,201,329 shares outstanding, as reported by Dyne Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Dyne Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Dyne Therapeutics, Inc.'s shareholder meeting held 2026-06-05, in the 2025-2026 proxy season, 249 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,962 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 99.1% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Dyne Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-08.

Dyne Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).